BioNTech SE (BNTX)
85.04
-2.61
(-2.98%)
USD |
NASDAQ |
Nov 12, 16:00
84.88
-0.16
(-0.19%)
After-Hours: 06:50
BioNTech Enterprise Value : 5.828B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 5.828B |
| November 11, 2026 | 6.475B |
| November 10, 2026 | 6.366B |
| November 09, 2026 | 6.440B |
| November 06, 2026 | 6.440B |
| November 05, 2026 | 6.031B |
| November 04, 2026 | 7.231B |
| November 03, 2026 | 6.294B |
| November 02, 2026 | 6.445B |
| October 30, 2026 | 6.604B |
| October 29, 2026 | 6.842B |
| October 28, 2026 | 6.559B |
| October 27, 2026 | 6.328B |
| October 26, 2026 | 6.279B |
| October 23, 2026 | 6.590B |
| October 22, 2026 | 6.975B |
| October 21, 2026 | 7.377B |
| October 20, 2026 | 7.347B |
| October 19, 2026 | 6.861B |
| October 16, 2026 | 6.489B |
| October 15, 2026 | 7.107B |
| October 14, 2026 | 6.725B |
| October 13, 2026 | 6.812B |
| October 12, 2026 | 8.505B |
| October 09, 2026 | 8.783B |
| Date | Value |
|---|---|
| October 08, 2026 | 7.568B |
| October 07, 2026 | 8.359B |
| October 06, 2026 | 8.478B |
| October 05, 2026 | 8.951B |
| October 02, 2026 | 8.768B |
| October 01, 2026 | 8.756B |
| September 30, 2026 | 9.115B |
| September 29, 2026 | 8.228B |
| September 28, 2026 | 8.357B |
| September 25, 2026 | 8.216B |
| September 24, 2026 | 8.402B |
| September 23, 2026 | 8.201B |
| September 22, 2026 | 8.806B |
| September 21, 2026 | 8.085B |
| September 18, 2026 | 7.598B |
| September 17, 2026 | 8.251B |
| September 16, 2026 | 7.540B |
| September 15, 2026 | 7.756B |
| September 14, 2026 | 8.301B |
| September 11, 2026 | 7.766B |
| September 10, 2026 | 7.683B |
| September 09, 2026 | 8.118B |
| September 08, 2026 | 8.251B |
| September 04, 2026 | 9.532B |
| September 03, 2026 | 9.311B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| Moderna, Inc. | 92.52B |
| Mereo BioPharma Group Plc | 23.19M |
| NuCana Plc | -20.99M |
| Immatics NV | 510.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 212.27M |
| Revenue (Quarterly) | 1.483B |
| Total Expenses (Quarterly) | 1.271B |
| EPS Diluted (Quarterly) | 0.8399 |
| Gross Profit Margin (Quarterly) | 71.11% |
| Profit Margin (Quarterly) | 14.31% |
| Earnings Yield | -8.08% |
| Normalized Earnings Yield | -6.262 |